“The current BN162 (Comirnaty) vaccine can induce antibody formation against the alpha and beta variants under laboratory conditions. No data is available on later variants. There has been no variant adaptation of the vaccine since the start of the vaccination campaign, and no adaptation is planned for the boosters. There is no general recommendation for a booster, and the benefits of vaccination must always be weighed up on an individual basis,”
BioNTech
BioNTech is a German biotechnology company specialized in the development and manufacturing of immunotherapies, particularly mRNA vaccines against infectious diseases and cancer.
Translation or original: 🇩🇪Click here
Quelle: Hier klicken
i
BioNTech Quote on Vaccine Efficacy Against Variants – What You Need to Know Now!
BioNTech explains Comirnaty's effectiveness against alpha and beta variants and the individual benefit assessment for boosters.
BioNTech SE, headquartered in Mainz, Germany, was founded in 2008 and is a leading developer of personalized cancer immunotherapies and mRNA-based vaccines, notably the COVID-19 vaccine Comirnaty developed in partnership with Pfizer.
Leave a Reply
Want to join the discussion?Feel free to contribute!